Welcome to our dedicated page for Inmune Bio news (Ticker: INMB), a resource for investors and traders seeking the latest updates and insights on Inmune Bio stock.
INmune Bio Inc. (NASDAQ: INMB) is a clinical-stage biotechnology company focused on developing novel immunotherapies that leverage the body’s innate immune system to fight cancer and other diseases. The company has a robust pipeline of product candidates, including INKmune™, INB03™, XPro™, and LIVNate™.
The company’s leading product, INKmune™, is designed to prime a patient’s natural killer (NK) cells to target and eliminate cancer cells that remain after initial treatment, thereby preventing relapse. By enhancing the functionality of NK cells, INKmune™ aims to boost the body’s ability to control residual disease, potentially extending patient survival.
INmune Bio’s INB03™ is a dominant-negative tumor necrosis factor (DN-TNF) inhibitor targeting high-risk breast cancers expressing MUC4 and triple-negative breast cancer (TNBC). Recent data presented at the American Association of Cancer Research in San Diego highlighted INB03™’s potential to decrease T cell and macrophage immune checkpoint proteins and reduce the metastatic potential of TNBC.
The company has also achieved significant milestones with XPro™, a treatment for Alzheimer’s Disease. INmune Bio recently announced the successful completion of the extended stability validation for continuous storage of XPro™ in solution, confirming its 24-month stability. The company is preparing for Phase III trials and commercial applications, leveraging established global distribution systems.
In addition, INmune Bio has entered into definitive agreements for the sale and purchase of nearly 1 million shares of its common stock and warrants, generating gross proceeds of approximately $9.7 million. These funds are earmarked to support ongoing clinical trials, including the Phase 2 trial for Alzheimer’s Disease and the Phase 1 trial for metastatic castration-resistant prostate cancer (mCRPC) using INKmune™.
The company’s management has focused on ensuring the safety and efficacy of their treatments. Recently, INKmune™ has shown promising results in initial clinical trials for mCRPC, with no significant adverse events reported, and approvals to proceed with further dosing cohorts.
For investors and stakeholders, INmune Bio provides a unique investment opportunity, combining cutting-edge science with a commitment to improving patient outcomes through innovative immunotherapy solutions. For more information, visit www.inmunebio.com.
INmune Bio, Inc. (NASDAQ: INMB) announced its second Phase 2 trial of XPro for Mild Cognitive Impairment (MCI), alongside a previously disclosed trial for mild Alzheimer’s disease (AD). The trial aims to include 90 patients and assess cognition using the Early AD/MCI Alzheimer's Cognitive Composite (EMACC). As of September 30, 2021, the company reported cash equivalents of $84.5 million and a net loss of approximately $9.5 million for Q3 2021. The firm is also advancing its INKmune™ platform and plans to host a conference call on November 3, 2021.
INmune Bio, Inc. (NASDAQ: INMB) is set to present multiple findings at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting, taking place from November 9-12 in Boston. Key presentations include a late-breaking oral presentation on the Early Mild Alzheimer’s Cognitive Composite as a primary cognitive endpoint in a phase 2 trial of XPro1595. Additionally, various poster sessions will examine neuroinflammation biomarkers, imaging measures, and methodologies for effective trial planning. XPro1595 aims to decrease neuroinflammation, potentially improving outcomes in Alzheimer's patients.
INmune Bio, Inc. (NASDAQ: INMB) announced a conference call scheduled for November 3, 2021 at 4:30 PM ET to discuss its third quarter results ending September 30, 2021, and provide a corporate update. The call will offer insights into the company’s clinical-stage immunology initiatives, including its DN-TNF and Natural Killer Cell Priming platforms. Investors can participate via phone or a live audio webcast, with a replay available until November 10. The company emphasizes the forward-looking nature of its statements regarding clinical trials and potential product approvals.
INmune Bio, Inc. (NASDAQ: INMB) announced that Mark Lowdell, PhD, Chief Scientific Officer and Chief Medical Officer, will participate in an oncology panel titled Improving Strategies to Harness the Immune System at the B. Riley Fall 2021 Best Ideas in Oncology Series.
The panel is scheduled for September 30, 2021, at 9:00am ET and is open to institutional investors. Registration is available here.
INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company, announced that its President and CEO, Raymond J. Tesi, MD, will present at two investor conferences in September 2021. The Oppenheimer Fall Healthcare Life Sciences & MedTech Summit will take place on September 22 at 1:15 PM ET, followed by the Cantor Fitzgerald Global Healthcare Conference on September 29 at 3:20 PM ET. Investors can arrange virtual one-on-one meetings through Oppenheimer or Cantor Fitzgerald. INmune Bio develops treatments targeting the innate immune system for various diseases.
INmune Bio has announced significant results from its Phase 1 study for XPro™, a selective DN-TNF inhibitor aimed at treating Alzheimer's disease (AD). The treatment resulted in a 46% decrease in CSF pT217, a promising biomarker for AD, and improved MRI metrics indicate remyelination. This data demonstrates reductions in biomarkers associated with neuroinflammation and neurodegeneration. A Phase 2 trial is set to begin by the end of 2021, enrolling 200 patients. Preliminary findings will be discussed in a webinar on September 7, 2021.
INmune Bio, Inc. (NASDAQ: INMB) announced positive results from the first patient receiving INKmune™ for high-risk myelodysplastic syndrome (MDS). The therapy successfully activated natural killer (NK) cells, generating memory-like NK (mlNK) cells as predicted by in vitro studies. The patient showed no adverse symptoms of Cytokine Release Syndrome (CRS) and had a doubling of NK cell numbers by day 8. The results indicate INKmune™ can effectively convert resting NK cells into more potent cancer-fighting cells, with further trials planned for additional patients.
INmune Bio, Inc. (NASDAQ: INMB) announced that President and CEO Raymond J. Tesi will present at the Canaccord Genuity 41st Annual Growth Conference from August 10 to 12, 2021. Tesi's presentation is scheduled for August 11, 2021, at 9:00 AM ET. The conference will also allow for virtual one-on-one meetings with INmune Bio representatives. The company focuses on developing treatments to enhance the innate immune system to combat diseases, with key product platforms aimed at various conditions including COVID-19, cancer, and Alzheimer's.
INmune Bio, Inc. (NASDAQ: INMB) announced that its President and CEO, Raymond J. Tesi, MD, will present at the BTIG Virtual Biotechnology Conference on August 9, 2021, at 1:00 PM Eastern Time. The conference will be held virtually on August 9-10, and attendees can schedule one-on-one meetings with INmune Bio through their BTIG representatives.
INmune Bio focuses on developing treatments that leverage the innate immune system to combat diseases, with ongoing clinical trials for various innovative therapies.
INmune Bio, Inc. (NASDAQ: INMB) reported its Q2 2021 financial results and provided a business update on August 4, 2021. The company is progressing towards a Phase 2 clinical trial of XPRO™ in mild Alzheimer’s patients, aiming to start by year-end. Recent financial highlights include a net loss of $6.7 million and increased R&D expenses of $4.5 million. The company raised $51.9 million in July 2021, securing funding for its upcoming trials. Notably, the first patient has been treated in the Phase 1 trial of INKmune for high-risk myelodysplastic syndrome.
FAQ
What is the current stock price of Inmune Bio (INMB)?
What is the market cap of Inmune Bio (INMB)?
What is INmune Bio Inc.'s primary focus?
What is INKmune™?
What recent achievements has INmune Bio reported?
What is the significance of INB03™?
How does INmune Bio plan to use the recent funding?
What are the key components of INmune Bio’s product platforms?
What ongoing clinical trials are INmune Bio conducting?
How does INKmune™ work?
Is INmune Bio’s technology approved by the FDA?
How can investors get more information about INmune Bio?
